Tout DSpace

Parcourir par sujet "long acting drug"

Voici les éléments 1-3 de 3

    • Do we overtreat mild persistent asthma? 

      Loukides, S.; Kostikas, K.; Bakakos, P. (2009)

    • SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics 

      Papaioannou A.I., Fouka E., Tzanakis N., Antoniou K., Samitas K., Zervas E., Kostikas K., Bartziokas K., Porpodis K., Papakosta D., Tzouvelekis A., Gerogianni I., Kotsiou O., Makris M., Rovina N., Vlachou G., Markatos M., Vittorakis S., Katsoulis K., Papanikolaou I., Afthinos A., Katsaounou P., Steiropoulos P., Latsios D., Dimakou K., Koukidou S., Hillas G., Tryfon S., Kallieri M., Georgopoulou A., Avarlis P., Bakakos P., Markopoulou K., Gaki E., Paspala A., Kyriakaki Z., Gourgoulianis K.I., Papiris S., Loukides S. (2022)
      Background: At the beginning of the pandemic, there have been considerable concerns regarding coronavirus disease 2019 (COVID-19) severity and outcomes in patients with severe asthma treated with biologics. Objective: To ...

    • Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD 

      Mandal J., Roth M., Papakonstantinou E., Sun Q., Costa L., Boeck L., Scherr A., Rakic J., Louis R., Milenkovic B., Boersma W., Kostikas K., Blasi F., Aerts J., Rohde G., Lacoma A., Torres A., Welte T., Tamm M., Stolz D. (2018)
      Long acting muscarinic antagonists (LAMA) are currently considered the therapeutic mainstay for patients with COPD and have been shown to improve clinical outcomes including symptoms, exercise capacity and airflow limitation. ...